SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001737287-22-000049
Filing Date
2022-07-12
Accepted
2022-07-12 16:05:05
Documents
12
Period of Report
2022-07-08
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K allo-20220708.htm   iXBRL 8-K 34656
  Complete submission text file 0001737287-22-000049.txt   170309

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20220708.xsd EX-101.SCH 1890
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20220708_lab.xml EX-101.LAB 24132
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20220708_pre.xml EX-101.PRE 12500
6 EXTRACTED XBRL INSTANCE DOCUMENT allo-20220708_htm.xml XML 10862
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 221079238
SIC: 2836 Biological Products, (No Diagnostic Substances)